<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inherited disorders associated with conjugated hyperbilirubinemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inherited disorders associated with conjugated hyperbilirubinemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Inherited disorders associated with conjugated hyperbilirubinemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jayanta Roy-Chowdhury, MD, MRCP, AGAF, FAASLD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Namita Roy-Chowdhury, PhD, FAASLD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Conditions that cause hyperbilirubinemia can be classified into those that result in a predominantly unconjugated hyperbilirubinemia and those that are associated with an elevation of both conjugated and unconjugated forms of bilirubin. (See  <a class="medical medical_review" href="/z/d/html/3615.html" rel="external">"Classification and causes of jaundice or asymptomatic hyperbilirubinemia"</a>.)</p><p>Excretion of conjugated bilirubin is impaired in a number of acquired conditions (such as alcoholic and viral hepatitis, biliary obstruction, cholestasis of pregnancy) and in inherited disorders (such as Dubin-Johnson syndrome, Rotor syndrome, benign recurrent intrahepatic cholestasis). This topic review will discuss the inherited disorders associated with conjugated hyperbilirubinemia. The other conditions are presented separately. (See appropriate topic reviews).</p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Elimination of conjugated bilirubin in bile is affected in several inherited disorders that work through different mechanisms. In all these situations, the abnormality of biliary excretion of bilirubin is shared with excretory defect of all or some other organic anions. Inherited syndromes of intrahepatic cholestasis commonly result from mutations in the following genes: <em>SERPINAI</em> (alpha 1- antitrypsin), <em>JAG1</em> (causing Alagille syndrome), <em>ATP8B1</em> (also known as <em>FIC1</em>), <em>ABCB11</em> (bile salt export pump [BSEP]), <em>MDR3</em> (<em>ABCB4</em>), and <em>MRP2</em> (causing Dubin-Johnson syndrome). The genetic basis of Rotor syndrome has not been identified [<a href="#rid1">1</a>].</p><p>Although Dubin-Johnson syndrome and Rotor syndrome have similar phenotypes (mild, fluctuating elevation of both unconjugated and conjugated bilirubin in plasma), in Dubin-Johnson syndrome biliary excretion of organic anions, except bile acids, is impaired, while Rotor syndrome is a disorder of hepatic storage. Other inherited conditions, like progressive familial intrahepatic cholestasis and benign recurrent intrahepatic cholestasis, cause conjugated hyperbilirubinemia as a consequence of reduced bile flow [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3"><span class="h1">DUBIN-JOHNSON SYNDROME</span><span class="headingEndMark"> — </span>In 1954, Dubin and Johnson [<a href="#rid3">3</a>] and Sprinz and Nelson [<a href="#rid4">4</a>] described patients with predominantly conjugated chronic hyperbilirubinemia that was not associated with hemolysis. The disorder occurs in all races and nationalities and both sexes [<a href="#rid4">4-7</a>]. It is rare except in Sephardic Jews in whom the incidence is approximately 1:3000 [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Dubin-Johnson syndrome is characterized clinically by mild icterus. Otherwise, patients are asymptomatic, although mild constitutional complaints such as vague abdominal pains and weakness can occur. Icterus can be so mild as to be noted only during intercurrent illnesses, pregnancy, or consumption of oral contraceptives [<a href="#rid6">6</a>]. Pruritus is not seen in this condition. Physical examination is usually normal except for the icterus, although hepatosplenomegaly is seen occasionally.</p><p class="headingAnchor" id="H5"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Routine clinical laboratory tests, including the complete blood count, serum albumin, cholesterol, alanine and aspartate aminotransferases, alkaline phosphatase, and prothrombin time, are normal [<a href="#rid5">5-7</a>]. Fasting and postprandial bile acid levels, which are sensitive indices of liver disease, are normal, reflecting the fact that the genetic abnormality does not affect the transport of most bile acids. Serum bilirubin concentrations are usually between 2 and 5 mg/dL but may decline to normal levels or be as high as 20 to 25 mg/dL. Approximately 50 percent of the serum bilirubin is conjugated. Of the conjugated bilirubin, a major fraction is bilirubin diglucuronide. In addition, covalently albumin-bound fraction is found in plasma. Bilirubinuria is common.</p><p>Oral cholecystography, using even a double dose of the contrast material is unsuccessful in visualizing the biliary system. Visualization may, however, be possible four to six hours after intravenous administration of Iodipamide [<a href="#rid8">8,9</a>].</p><p>Grossly, the liver is black [<a href="#rid4">4</a>]. It is histologically normal except for the presence of a dense pigment  (<a class="graphic graphic_picture graphicRef67304" href="/z/d/graphic/67304.html" rel="external">picture 1</a>). Electron microscopy reveals that the pigment is contained in the lysosomes [<a href="#rid10">10</a>]. Electron spin resonance spectroscopy suggests that the pigment is composed of polymers of epinephrine metabolites [<a href="#rid11">11</a>]. Computerized tomography of patients with Dubin-Johnson syndrome shows a significantly higher attenuation as compared with normal subjects [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Organic anion transport defect</span><span class="headingEndMark"> — </span>Uptake of organic anions at the sinusoidal surface of hepatocytes is normal in Dubin-Johnson syndrome, as shown by normal initial plasma clearance of intravenously administered bilirubin [<a href="#rid13">13,14</a>], bromosulfophthalein (BSP) [<a href="#rid7">7,14,15</a>], dibromosulfophthalein (DBSP) [<a href="#rid15">15</a>], <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">indocyanine green</a> (ICG) [<a href="#rid14">14,15</a>], and 125I-labeled rose bengal [<a href="#rid15">15</a>]. However, in 90 percent of patients, plasma BSP concentration shows a secondary increase 90 minutes after intravenous administration [<a href="#rid6">6,7,16</a>]. The secondary rise reflects regurgitation of glutathione-conjugated BSP from hepatocytes to the plasma. A similar secondary rise is seen after intravenous injection of unconjugated bilirubin [<a href="#rid11">11,14</a>], but not after injection of substances, such as DBSP, ICG, and 125I-labeled rose bengal, which are not conjugated prior to excretion [<a href="#rid14">14,15</a>]. Although the secondary rise is characteristic of Dubin-Johnson syndrome, it is not diagnostic by itself, because it is also seen in hepatobiliary cholestatic disorders. In addition, BSP testing is no longer performed.</p><p class="headingAnchor" id="H7"><span class="h2">Urinary coproporphyrin excretion</span><span class="headingEndMark"> — </span>The total urinary coproporphyrin is normal in Dubin-Johnson syndrome, but over 80 percent of it is coproporphyrin I, in contrast to normal subjects in whom 75 percent of urinary coproporphyrin is coproporphyrin III [<a href="#rid17">17,18</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Clotting factor VII deficiency</span><span class="headingEndMark"> — </span>Reduced prothrombin activity, resulting from lower levels of clotting factor VII, is found in 60 percent of the patients with Dubin-Johnson syndrome. Factor VII deficiency is most common among Sephardic Jews originating from Iran, Iraq, and the neighboring areas [<a href="#rid19">19-21</a>]. However, reduced factor VII levels are also found among patients from other communities. In some families, the two disorders segregate independently, indicating that the linkage is not tight.</p><p class="headingAnchor" id="H9"><span class="h2">Animal models</span><span class="headingEndMark"> — </span>A metabolic defect in Corriedale sheep resembles what is seen in Dubin-Johnson syndrome. Organic anion transport defects and urinary coproporphyrin excretion patterns are similar to patients with Dubin-Johnson syndrome [<a href="#rid22">22-26</a>]. However, the most widely used model is the TR-rat [<a href="#rid25">25-29</a>]. In these rats, biliary excretion of conjugated bilirubin and other organic anions is impaired. The predominant coproporphyrin in urine is coproporphyrin I [<a href="#rid17">17</a>].</p><p>Lysosomal accumulation of black pigments in the liver occurs after feeding a diet enriched with amino acids [<a href="#rid25">25</a>]. Breeding studies show an autosomal recessive inheritance pattern and suggest that the abnormality of a single gene is responsible for the disease. The Golden lion tamarin monkey, which manifests conjugated hyperbilirubinemia, is another animal model for Dubin-Johnson syndrome [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Molecular mechanism</span><span class="headingEndMark"> — </span>Non-bile acid organic anions, such as conjugated bilirubin and other glucuronide or glutathione conjugated substances, are transported into the bile canaliculus from the hepatocyte by the multidrug resistance related protein, <em>MRP2</em> (also known as the canalicular multispecific organic anion transporter, cMOAT), which is encoded by the <em>ABCC2</em> gene  (<a class="graphic graphic_figure graphicRef50804" href="/z/d/graphic/50804.html" rel="external">figure 1</a>) [<a href="#rid23">23,31-34</a>].</p><p>The transport is ATP-dependent and is achieved against high concentration gradients. The electrochemical gradient created by the negative intracellular potential of -35 mV also contributes to the transport of bilirubin glucuronides [<a href="#rid22">22,28,35</a>] into the bile canaliculus. <em>MRP2</em> is one of the ATP-binding cassette (ABC) transporters [<a href="#rid36">36</a>]. Direct evidence for its involvement in canalicular transport came from the discovery of a frameshift mutation in the gene encoding it in the TR-rat [<a href="#rid37">37</a>].</p><p>The human <em>MRP2</em> gene has been localized to chromosome 10q23-q24 [<a href="#rid38">38</a>]. The exon-intron organization has been elucidated [<a href="#rid39">39,40</a>] and the human cDNA has been isolated based upon homology with rat <em>MRP2</em> [<a href="#rid41">41</a>]. Several different mutations  (<a class="graphic graphic_figure graphicRef60737" href="/z/d/graphic/60737.html" rel="external">figure 2</a>) have been identified in this gene in patients with Dubin-Johnson syndrome [<a href="#rid39">39-44</a>]. Mutations in the ATP-binding region, critical for the functioning of the protein, form a significant proportion of the genetic lesions identified [<a href="#rid40">40,42</a>]. One mutation causes impaired maturation and mislocalization of the protein (mutation "h" in the figure)  (<a class="graphic graphic_figure graphicRef60737" href="/z/d/graphic/60737.html" rel="external">figure 2</a>) [<a href="#rid45">45</a>]. A mutation at an intronic splice donor site was identified in a patient with Dubin-Johnson syndrome [<a href="#rid43">43</a>]. Autosomal recessive inherence has been confirmed based upon urinary coproporphyrin analysis in families of affected individuals [<a href="#rid46">46,47</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of Dubin-Johnson syndrome can be made by documenting conjugated hyperbilirubinemia (where at least 50 percent of the total bilirubin is the direct fraction) while the rest of the "liver function profile" (serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, albumin, and prothrombin time) are normal, together with the characteristic urinary coproporphyrin excretion. (See <a class="local">'Urinary coproporphyrin excretion'</a> above and <a class="local">'Diagnosis and differentiation from Dubin-Johnson syndrome'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Dubin-Johnson syndrome is a benign condition and no treatment is required. However, it is important to recognize the condition so as not to confuse it with other hepatobiliary disorders associated with conjugated hyperbilirubinemia.</p><p class="headingAnchor" id="H13"><span class="h1">ROTOR SYNDROME</span><span class="headingEndMark"> — </span>Rotor syndrome is a rare disorder, first described in 1948 by Rotor, Manahan, and Florentin. Since then, it has been reported in several nationalities and races.</p><p class="headingAnchor" id="H14"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>The syndrome is characterized by chronic conjugated and unconjugated hyperbilirubinemia without evidence of hemolysis [<a href="#rid48">48</a>]. Although Rotor syndrome had been thought previously to be a variant of Dubin-Johnson syndrome [<a href="#rid49">49</a>], the two conditions are now understood to be different entities [<a href="#rid50">50</a>]. In Rotor syndrome, there is a defect in hepatic storage of conjugated bilirubin, which leaks into the plasma, resulting in hyperbilirubinemia. Rotor syndrome is also a benign condition.</p><p class="headingAnchor" id="H15"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Serum alkaline phosphatase, alanine aminotransferase, aspartate amino transferase and gamma-glutamyl transpeptidase levels are normal. Plasma clearance of bromophthalein sodium (BSP) is delayed, but unlike in Dubin-Johnson syndrome, biphasic peaks are not seen [<a href="#rid51">51</a>]. Patients exhibit prolonged retention of intravenously injected unconjugated bilirubin and <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">indocyanine green</a> [<a href="#rid52">52</a>]. Transport studies for BSP show a 50 percent reduction in transport maximum of this compound in Rotor syndrome, compared to almost no biliary transport in Dubin-Johnson syndrome [<a href="#rid51">51,52</a>]. In contrast to the finding in Dubin-Johnson syndrome, the gallbladder is usually visualized by oral cholecystography [<a href="#rid49">49</a>].</p><p>Liver histology is normal [<a href="#rid49">49</a>]. The absence of dark melanin-like pigments differentiates this disorder from Dubin-Johnson syndrome. However, liver biopsy is not required for the differentiation, which can be done on the basis of urinary coproporphyrin analysis (see below).</p><p class="headingAnchor" id="H16"><span class="h2">Urinary coproporphyrin excretion</span><span class="headingEndMark"> — </span>The total urinary coproporphyrin excretion is increased to 250 to 500 percent of normal and coproporphyrin I constitutes approximately 65 percent of urinary porphyrins [<a href="#rid50">50,53</a>]. In obligate heterozygotes, the pattern of excretion is intermediate between that of patients with Rotor syndrome and controls. With respect to coproporphyrin excretion, Rotor syndrome is inherited as an autosomal recessive condition and is distinct from Dubin-Johnson syndrome [<a href="#rid53">53</a>]. However, the molecular basis of the hepatic storage defect in Rotor syndrome has not been elucidated.</p><p class="headingAnchor" id="H177556382"><span class="h2">Molecular mechanism</span><span class="headingEndMark"> — </span>Bilirubin entering the liver sinusoids is extracted efficiently by hepatocytes that are closest to the points of entry, the portal vein and hepatic artery. As canalicular excretion of conjugated bilirubin is rate limiting in bilirubin excretion, this leads to the possibility of saturation of the excretion process. Bilirubin excretory capacity of the liver is increased by transport of conjugated bilirubin back into the sinusoidal blood through the sinusoidal surface of the hepatocytes via the ATP-hydrolysis dependent pump, ABCC3. Bilirubin undergoes re-uptake by hepatocytes downstream to the sinusoidal blood flow via organic anion transporter proteins 1B1 and 1B3 (OATP1B1 and OATP1B3), encoded by <em>SLCO1B1</em> and <em>SLCO1B3</em>, respectively. This re-uptake process results in recruitment of additional hepatocytes downstream to the sinusoidal blood flow, thereby increasing the bilirubin excretory capacity of the liver [<a href="#rid54">54</a>]. OATP1B1 and OATP1B3 have functional overlap. Inactivating mutations or deletion of both <em>SLCO1B1</em> and <em>SLCO1B3 </em>disrupts this re-uptake process, resulting in Rotor syndrome [<a href="#rid55">55</a>].</p><p>Notably, mutations of OATP1B1 or OATP1B3 alone do not cause jaundice. However, these transporters mediate the uptake of many other compounds, including several drugs. Reduced-activity OATP1B1 resulting from polymorphisms can result in life-threatening drug toxicities, such as statin-associated myopathy [<a href="#rid56">56</a>]. Therefore, great caution should be used in treating patients with Rotor syndrome with drugs that undergo transport by these proteins.</p><p class="headingAnchor" id="H17"><span class="h2">Diagnosis and differentiation from Dubin-Johnson syndrome</span><span class="headingEndMark"> — </span>Dubin-Johnson and Rotor syndrome should be suspected in patients with mild hyperbilirubinemia (with a direct-reacting fraction of approximately 50 percent) in the absence of other abnormalities of standard liver function tests. Normal levels of serum alkaline phosphatase and gamma-glutamyltranspeptidase help to distinguish these conditions from disorders associated with biliary obstruction.</p><p>The urinary coproporphyrin excretion pattern assists in the diagnosis and in the distinction between these disorders. In Dubin-Johnson syndrome, the total urinary coproporphyrin excretion is normal but 80 percent is coproporphyrin I (in normal subjects 75 percent of urinary porphyrins are coproporphyrin III). In contrast, in patients with Rotor syndrome, total urinary coproporphyrins are increased to 250 to 500 percent of normal with approximately 65 percent being coproporphyrin I.</p><p>The plasma BSP clearance can also be used to aid in the distinction between these disorders, although it is no longer available for routine clinical use. In Dubin-Johnson syndrome, plasma BSP clearance shows a characteristic biphasic peak. Retention of the dye is nearly normal 45 minutes after injection, but there is a secondary peak at 90 minutes. In Rotor syndrome, there is increased retention at 45 minutes and no secondary peak is seen.</p><p>Liver biopsy is not necessary for the diagnosis of either condition. However, if a biopsy is performed for other clinical indications, the dense pigmentation of the liver seen in Dubin-Johnson syndrome  (<a class="graphic graphic_picture graphicRef67304" href="/z/d/graphic/67304.html" rel="external">picture 1</a>) distinguishes it from Rotor syndrome.</p><p class="headingAnchor" id="H18"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>In both Dubin-Johnson and Rotor syndromes, serum bilirubin levels may increase during pregnancy, requiring differentiation from cholestasis of pregnancy. The latter is usually associated with pruritus, which is not a feature of Dubin-Johnson or Rotor syndromes [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>As in Dubin-Johnson syndrome, Rotor syndrome does not require treatment. However, the diagnosis is important to avoid confusion with other hepatobiliary diseases.</p><p class="headingAnchor" id="H20"><span class="h1">FAMILIAL HEPATOCELLULAR CHOLESTASIS</span></p><p class="headingAnchor" id="H21"><span class="h2">Progressive familial intrahepatic cholestasis</span><span class="headingEndMark"> — </span>Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of disorders, characterized by defective secretion of bile acids or other components of bile. With the exception of benign recurrent cholestasis (BRIC), these disorders usually present during infancy or childhood, and are associated with growth failure and progressive liver disease. Many patients present with a coagulopathy due to vitamin K malabsorption. Intractable pruritus is a dominant feature in the early stages of PFIC I and II.</p><p class="headingAnchor" id="H22"><span class="h3">Progressive familial intrahepatic cholestasis type I</span><span class="headingEndMark"> — </span>Progressive familial intrahepatic cholestasis type I (PFIC I), also known as Byler disease [<a href="#rid58">58</a>] and Greenland familial cholestasis [<a href="#rid59">59</a>], is caused by a mutation in the P-type ATPase gene (<em>ATP8B1</em>), <em>FIC1</em>, which has been localized to chromosome 18q21 [<a href="#rid60">60</a>]. <em>FIC1</em> is located in the canalicular membrane of hepatocytes and in cholangiocytes, and couples the hydrolysis of ATP to the translocation of acidic phospholipids [<a href="#rid61">61</a>]. How the mutation of <em>FIC1</em> causes cholestasis and abnormal bile acid transport is not clear.</p><p class="headingAnchor" id="H23"><span class="h3">Progressive familial intrahepatic cholestasis type II</span><span class="headingEndMark"> — </span>Progressive familial intrahepatic cholestasis type II (PFIC II) resembles Byler disease clinically but occurs in non-Byler families, mainly in the Middle East and Europe. It is caused by defects in the gene that codes for the sister P-glycoprotein (SPGP) [<a href="#rid62">62</a>], also known as bile salt export pump (BSEP)  (<a class="graphic graphic_figure graphicRef50804" href="/z/d/graphic/50804.html" rel="external">figure 1</a>), which is an ATP-dependent transporter of bile acids from the hepatocytes into the bile canaliculus [<a href="#rid2">2</a>]. The SPGP gene (<em>ABCB11</em>) has been localized to chromosome 2q24 [<a href="#rid62">62</a>]. Over 80 different mutations in SPGP have been described in patients with PFIC II [<a href="#rid63">63</a>]. Studies in rats suggest that the mechanisms leading to impaired bile acid transport vary depending upon the specific mutation [<a href="#rid64">64</a>].</p><p>PFIC I and PFIC II are both associated with life-threatening cholestasis. Interestingly, despite this, serum gamma-glutamyl transpeptidase levels are normal or nearly so in both these disorders [<a href="#rid65">65</a>].</p><p>Hepatocellular carcinoma (HCC), which is rare in young children, has been reported in ten children less than five years of age with PFIC-II. Thus, <em>ABCB11</em> mutations represent a previously unrecognized risk for HCC in young children [<a href="#rid66">66</a>].</p><p>Liver transplantation ameliorates all manifestations of PFIC II, specifically hepatic expression of SPGP. However, in approximately 8 percent of children with PFIC II caused by different <em>ABCB11</em> mutations, the disease recurred after liver transplantation, probably as a consequence of the development of high titer antibodies against BSEP and deposition of these antibodies, as well as the complement component protein C4d in liver sinusoids [<a href="#rid67">67-70</a>]. Recurrent BSEP disease may be ameliorated by antibody-depletion therapies, such as a monoclonal antibody against the CD20 antigen of B-cells (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) with or without plasmapheresis [<a href="#rid70">70</a>]. As in the case of <em>ATP8B1</em>, some mutations of <em>ABCB11</em> are associated with a more benign and recurrent course, presenting in adult cases. As in the case of <em>ATP8B1</em>, some mutations of <em>ABCB11</em> are associated with a more benign and recurrent course, presenting in adult cases. (See <a class="local">'Benign recurrent intrahepatic cholestasis'</a> below.)</p><p>Treatment with 4-phenylbutyrate may be beneficial in the subset of patients with <em>ABCB11</em> missense mutations that affect BSEP trafficking to the canalicular membrane. In transfected cell lines, 4-phenylbutyrate has been shown to partially correct mistrafficking of BSEP [<a href="#rid71">71,72</a>]. In a study of four patients with this type of mutation, treatment with 4-phenylbutyrate resulted in improvements in pruritus, serum bile acid concentration, and serum liver tests [<a href="#rid73">73</a>]. In addition, canalicular localization of BSEP was demonstrated by immunostaining of liver biopsies obtained in three of the patients after 4-phenylbutyrate therapy.</p><p class="headingAnchor" id="H24"><span class="h3">Progressive familial intrahepatic cholestasis type III</span><span class="headingEndMark"> — </span>Progressive familial intrahepatic cholestasis type III (PFIC III), involves mutations in the ABCB4 gene (also known as multidrug resistance protein-3 P-glycoprotein [MDR3 or PGY3])  (<a class="graphic graphic_figure graphicRef50804" href="/z/d/graphic/50804.html" rel="external">figure 1</a>) [<a href="#rid74">74</a>]. MDR3 is thought to replenish the phosphatidylcholine in the outer lipid membrane of the bile canaliculus by translocating it from the inner lipid layer. However, bile salt secretion remains normal. In the absence of phosphatidylcholine translocation, bile acids are thought to damage the canalicular membrane, causing progressive destruction of small bile ducts [<a href="#rid75">75,76</a>]. PFIC III, which is caused by mutations on both alleles, is distinguished from PFIC I, BRIC, and PFIC II by the markedly elevated gamma-glutamyl transpeptidase activity in the serum [<a href="#rid65">65</a>].</p><p>Heterozygous mutations in ABCB4 can reduce biliary phospholipid concentration, resulting in increased risk for cholesterol stones, microlithiasis, or sludge, a syndrome known as low phospholipid-associated cholestasis (LPAC). LPAC should be suspected in patients presenting with cholelithiasis before age 40, recurrence after cholecystectomy, and intrahepatic hyperechogenic foci compatible with sludge or microlithiasis [<a href="#rid77">77</a>]. Many patients have a family history of cholelithiasis in first-degree relatives or a clinical history of intrahepatic cholestasis of pregnancy [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a>.)</p><p>Approximately one-third of adult patients presenting with unexplained cholestasis have mutations in the coding region of at least one ABCB4 allele [<a href="#rid79">79</a>]. ABCB4 mutations also cause acute recurrent biliary pancreatitis, biliary cirrhosis, and fibrosing cholestatic liver disease in adults with or without biliary symptoms [<a href="#rid79">79,80</a>].</p><p class="headingAnchor" id="H1875568127"><span class="h3">Progressive familial intrahepatic cholestasis type IV</span><span class="headingEndMark"> — </span>Severe chronic cholestatic liver disease, with serum GGT levels that were low for the degree of cholestasis (similar to that found in PFIC I and II) were reported in 33 children from 29 families [<a href="#rid81">81</a>]. Genetic analysis showed protein-truncating mutations in the <em>TJP2 </em>gene that expresses tight junction protein 2. The truncation of TJP2 protein resulted in failure of its incorporation in tight junctions delimiting the bile canaliculi. This causes the failure of claudin1 (CLDN1) to localize in the cholangiocyte-cholangiocyte borders and margins of bile canaliculi. Interestingly, the pathology appears to be limited to the liver. There were no mutations of <em>ABCB11 </em>or <em>ATP8B1 </em>genes that are responsible for PFIC I and PFIC II, respectively. As in many other rare monogenic disorders, there was a high incidence of consanguinity, which was observed in 18 parents in the 29 families. Two infants with PFIC IV have been reported to develop hepatocellular carcinoma [<a href="#rid82">82</a>]. One had a single tumor and the other had a large number of multifocal tumors.  </p><p class="headingAnchor" id="H25"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Initial care for patients with PFIC addresses the nutritional problems and pruritus caused by chronic cholestasis. Fat-soluble vitamin supplementation and monitoring is necessary, as for other forms of chronic cholestasis. Initial therapy for patients with all forms of PFIC is <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a>, which may improve liver function in some patients, especially those with PFIC III who often have less severe disease [<a href="#rid83">83-85</a>].</p><p>Pruritus may be the predominant symptom in many patients with PFIC. Although the mechanism of pruritus of cholestasis is not fully understood, several classes of pruritogens have been recognized: bile acids; the enzyme autotaxin, which cleaves lysophosphatidylcholine, forming lysophosphatidic acid [<a href="#rid86">86</a>]; endogenous opioids; the neurotransmitter serotonin; and unidentified pruritogens. A sequential approach is recommended for the treatment of pruritus [<a href="#rid87">87</a>]. </p><p>The first line of treatment consists of modification or depletion of the bile salt pool. <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">Ursodeoxycholic acid</a> (UCDA), 15 mg/kg daily, a natural hydrophilic bile acid, should be tried to partially replace the endogenous bile acid pool by competition for ilial bile acid absorption [<a href="#rid88">88</a>]. If pruritus is not relieved by UCDA, depletion of the bile acid pool should be attempted. Conventionally, this has been done by administering <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> (1 to 4 g/day), an oral bile acid binding resin that forms non-absorbable micelles with the bile acids in the intestines, thereby disrupting the enterohepatic recycling of bile acids [<a href="#rid89">89</a>]. Cholestyramine can cause constipation and can interfere with the absorption of fat-soluble vitamins and certain drugs. Therefore, it should be administered at least one hour before or four to six hours after meals or other drugs. An alternative approach consists of pharmacologic inhibition of ileal bile acid transport by a non-absorbable drug, <a class="drug drug_general" data-topicid="132116" href="/z/d/drug information/132116.html" rel="external">odevixibat</a>. Odevixibat (40 mcg/kg) is administered orally once daily in the morning with a meal. If after three months the clinical response remains inadequate, the dose may be increased in 40 mcg/kg increments up to 120 mcg/kg once-daily, not exceeding 6 mg daily. Odevixibat is effective in most types of PFIC, except in PFIC II, because severe BSEP deficiency may preclude biliary secretion of significant amounts of bile salts. Odevixibat causes loose bowel movements in about 10 percent of the recipients because of the effect of unabsorbed bile salts on the colonic epithelium. If cholestyramine is used in addition to odevixibat, it should be administered at least four hours apart from odevixibat. </p><p>The second line of therapy aims at increasing the metabolism and excretion of pruritogens using rifampicin, a pregnane X-receptor (PXR) agonist and a potent inducer of key enzymes in hepatic and intestinal detoxification, and the export pump MRP2 [<a href="#rid90">90</a>]. Rifampicin reduces serum autotaxin levels. Because of an approximately 5 percent incidence of drug-induced liver injury in children, rifampicin should be initiated at a low dose (150 mg/day), with serial monitoring of serological liver tests and blood count, before escalating the dose to maximum of 600 mg/day [<a href="#rid90">90</a>]. If <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> therapy fails to reduce itching, the third line of therapy should be <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a>, the oral opioid antagonist, at a dose of 50 mg daily [<a href="#rid91">91</a>]. Naltrexone should be started at a low dose of 12.5 mg and increased by one-quarter every three to seven days to avoid the self-limited withdrawal-like syndrome in the first days of treatment caused by dissociation of endogenous opioids from their receptors [<a href="#rid92">92</a>]. To prevent a "break-through" phenomenon during long-term therapy, naltrexone may be withheld two days a week. Finally, the selective serotonin reuptake inhibitor <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, which increases neurotransmitter concentrations within the central nervous system [<a href="#rid93">93</a>], may be considered as a fourth-line treatment for patients resistant to above mentioned treatments. Sertraline is started at 25 mg/day, increasing gradually to 75 to 100 mg/day, and can be also used in addition to rifampicin therapy.</p><p>In some patients, pruritus may be refractory to pharmacologic intervention. In these patients, surgical procedures to interrupt the enterohepatic circulation of bile acids are often successful. This can be done by diverting part of the bile flow to an external fistula, where it is discarded [<a href="#rid94">94-96</a>]. Biochemical improvements are often seen, suggesting that the diversion procedure might slow the progression of liver disease [<a href="#rid96">96-98</a>]. Liver transplantation is generally curative for patients with PFIC I, II, and IV. However, patients with PFIC I may have ongoing disease due to the extrahepatic expression of FIC I [<a href="#rid99">99,100</a>].</p><p>Liver transplantation is an important option for patients with end-stage liver disease due to PFIC, and for some patients with pruritus that is unresponsive to the measures described above [<a href="#rid101">101</a>]. Liver transplantation is generally curative for patients with PFIC. However, patients with PFIC I may have ongoing disease due to the extrahepatic expression of FIC I [<a href="#rid102">102</a>].</p><p>Transplantation of normal hepatocytes to repopulate the liver and replace the dying cells has been tried in a mouse model of PFIC III, with partial restoration of phospholipid secretion in the bile [<a href="#rid103">103,104</a>].</p><p>Patients presenting with cholelithiasis associated with <em>ABCB4</em> mutations may require endoscopic or surgical removal of gallstones. Replacement of endogenous lithogenic bile acids with hydrophilic bile acids, such as <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a>, has been proposed for prevention of cholelithiasis in these patients. Ursodeoxycholic acid (15 mg/kg body weight daily) has been used successfully in several adult patients [<a href="#rid78">78,79</a>].</p><p class="headingAnchor" id="H26"><span class="h2">Benign recurrent intrahepatic cholestasis</span><span class="headingEndMark"> — </span>Benign recurrent intrahepatic cholestasis (BRIC), first described in 1959, is characterized by intermittent cholestatic episodes [<a href="#rid105">105</a>]. Age at first presentation ranges from infancy to late adulthood. The number of attacks can range from several episodes per year to one episode in a decade [<a href="#rid106">106-109</a>]. During the attacks, the patients present with conjugated hyperbilirubinemia, malaise, anorexia, pruritus, weight loss, and malabsorption. Laboratory tests reveal biochemical evidence of cholestasis without severe hepatocellular injury [<a href="#rid107">107,110,111</a>]. Such episodes last for weeks to months followed by a complete clinical, biochemical, and histologic normalization. In a given patient, recurrent attacks resemble each other in symptoms, signs, and duration, although the severity and frequency of the episodes appear to decrease with age. BRIC has long been thought to be associated with intrahepatic cholestasis of pregnancy and cholestasis associated with use of oral contraceptives. In one study, 11 members of kindred of whom three members had been affected by BRIC developed intrahepatic cholestasis of pregnancy, cholestasis associated with oral contraceptives, or both [<a href="#rid106">106</a>].</p><p>Liver histology reveals noninflammatory intrahepatic cholestasis without fibrosis, regardless of the number and severity of attacks. During remission, liver histology returns to normal whether examined by light or electron microscopy [<a href="#rid112">112</a>].</p><p>Family studies suggest a recessive inheritance pattern. Surprisingly, this relatively benign disorder was also found to be associated with mutations of <em>ATP8B1</em> (FIC <em>I</em>) and <em>ABCB11</em> (BSEP) genes, which are associated with PFIC-1 and PFIC-II respectively. Mutations in <em>ABCB11</em> (BSEP gene) have been also associated with BRIC [<a href="#rid113">113</a>]. As an example, a patient with clinical features of BRIC was found to have two different mutations on the two alleles of the <em>ABCB11</em>: A E186G substitution (previously described in a BRIC-2 case) and a V444A substitution (linked to intrahepatic cholestasis of pregnancy). The compound heterozygosity led to the absence of BSEP in bile canaliculi of hepatocytes. Bile salt excretion was reduced [<a href="#rid114">114</a>].</p><p>It has been proposed that BRIC caused by mutations of <em>ATP8B1</em> and <em>ABCB11</em> should be termed BRIC-1 and BRIC-2, respectively [<a href="#rid113">113</a>]. There are clinical differences between these two subtypes suggesting that it may be appropriate to subclassify BRIC into at least two distinct disorders (BRIC type 1 and 2). Pancreatitis is a known extrahepatic manifestation in BRIC caused by the <em>ATPB1</em> mutations but not in BRIC patients with mutations in <em>ABCB11</em>. Similarly, cholelithiasis has been described in patients with the <em>ABCB11</em> mutation but not in those with the <em>ATP8B1</em> mutation [<a href="#rid115">115</a>].</p><p class="headingAnchor" id="H27"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>There is no specific treatment for BRIC. Liver transplantation is generally not considered because of the episodic and non-progressive nature of the disease, although the pruritus can be severe enough for the patient to seek liver transplantation. Short-term nasobiliary drainage has been reported to improve pruritus in a patient with BRIC, presumably by normalizing serum bile salt concentrations [<a href="#rid116">116</a>]. Rapid termination of cholestatic episode was reported in a 34-year-old man with BRIC and secondary renal impairment, following extracorporeal albumin dialysis in a molecular absorbent recycling system (MARS) [<a href="#rid117">117</a>]. Administration of colestimide, an anion exchange resin that inhibits intestinal bile acid<em> </em>absorption, resulted in rapid remission of the cholestatic episode in one patient [<a href="#rid118">118</a>].</p><p class="headingAnchor" id="H28"><span class="h1">BILE CANALICULAR AND STRUCTURAL ANOMALIES OF KNOWN GENETIC BASIS</span><span class="headingEndMark"> — </span>The genetic basis of two disorders involving bile canalicular and structural anomalies has been described: Alagille syndrome and abnormalities of Villin gene expression.</p><p class="headingAnchor" id="H29"><span class="h2">Alagille syndrome</span><span class="headingEndMark"> — </span>Alagille syndrome is characterized by the paucity of interlobular bile ducts and the following associated features [<a href="#rid119">119-122</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic cholestasis (approximately 90 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac anomalies, most commonly peripheral pulmonic stenosis (85 to 91 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Butterfly vertebrae (39 to 87 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Posterior embryotoxon (prominent Schwalbe line) of the eye (61 to 88 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Dysmorphic facies, consisting of broad nasal bridge, triangular facies, and deep-set eyes (77 to 95 percent)</p><p></p><p>Other minor abnormalities seen in these patients consist of growth and intellectual disability, developmental delay, renal disease, and pancreatic insufficiency. The syndrome is inherited as an autosomal dominant characteristic. The gene responsible for the condition (<em>JAG 1</em>) has been mapped to chromosome 20p12 [<a href="#rid123">123</a>]. </p><p>Severe liver disease is a major cause of morbidity in patients with Alagille syndrome. Approximately 85 percent of patients present before six months of age with jaundice and failure to thrive, or cardiovascular symptoms. Chronic cholestasis is associated with elevation of serum bilirubin, gamma-glutamyltranspeptidase and alkaline phosphatase levels, and to a lesser extent, transaminase levels. As in all cases of intrahepatic cholestasis, lipoprotein X is present in plasma. In addition, lecithin cholesterol acyltransferase activity is reduced in many, but not all, patients [<a href="#rid124">124</a>] (see  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants", section on 'Alagille syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/139432.html" rel="external">"Alagille syndrome", section on 'Clinical features'</a>). Serum bilirubin levels often decrease after the first year of life, but other components of cholestasis may continue. Pruritus can be severe and unrelenting, requiring specific treatment. A study of 163 patients has compared the impact of liver involvement on morbidity and mortality in patients with Alagille syndrome [<a href="#rid125">125</a>]. The morbidity was significantly higher in patients who presented with neonatal cholestatic jaundice as compared to those who developed cholestatic jaundice later in life. Such patients also experienced worse short-term survival without transplantation.</p><p class="headingAnchor" id="H1159276379"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Ileal bile acid transporter (IBAT) <a class="drug drug_general" data-topicid="133173" href="/z/d/drug information/133173.html" rel="external">maralixibat</a> can be used as the first line of therapy of severe pruritus in patients with Alagille syndrome [<a href="#rid126">126</a>]. Maralixibat is available in a liquid formulation, which is administered 30 minutes before breakfast. The starting dose is 190 mcg/kg once daily, which is increased after one week to 380 mcg/kg as tolerated. The maximum daily dose for patients above 70 kg is 28.5 mg per day. As with other IBAT inhibitors, effect of the unabsorbed bile salts on colonic epithelium may result in diarrhea. Additionally, bile salt depletion can cause malabsorption of fat and fat-soluble vitamins A, D, E, and K, which may need supplementation. Although maralixibat is poorly absorbed, in some cases, it may exacerbate abnormalities of liver tests. Therefore, serum bilirubin, alanine and aspartate transaminases, alkaline phosphatase, gamma-glutamyl transpeptidase and prothrombin time (INR) should be determined before initiation of treatment and intermittently during the course of therapy. (See  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants", section on 'Alagille syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/139432.html" rel="external">"Alagille syndrome", section on 'Pruritus'</a>.)</p><p>A significant number of patients with Alagille syndrome continue to have progressive liver synthetic dysfunction, osteodystrophy, or massive variceal bleeding, and eventually require liver transplantation [<a href="#rid125">125,127</a>].</p><p><a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">Ursodeoxycholic acid</a> has been reported to be associated with symptomatic and biochemical improvement in a small number of cases [<a href="#rid128">128,129</a>], but larger clinical trials are needed to determine precisely its place in the management of these patients. <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">Cholestyramine</a> does not appear to be useful, and does not correct the lipid abnormalities [<a href="#rid124">124</a>].</p><p class="headingAnchor" id="H30"><span class="h2">Abnormal villin expression</span><span class="headingEndMark"> — </span>This inherited disease is characterized by a biliary atresia-like presentation with special ultrastructural features. In a review of 50 children who underwent orthotopic liver transplantation for a clinical diagnosis of biliary atresia, three were found to have aberrant ultrastructural findings and a lack of villin expression in the bile canaliculi, as determined by immunohistochemical staining [<a href="#rid130">130</a>]. Each of these patients had clinical features of cholestasis including elevations in serum alkaline phosphatase (356 to 788 international units), gamma-glutamyl transpeptidase (76 to 203 U/L) and bilirubin (16 to 26 mg/dL). All patients had cirrhosis at the time of liver transplantation at the age of two to five years. Histologic examination of the liver showed paucity or absence of bile ducts and only a moderate degree of portal fibrosis at the age of three months, which distinguished these cases from classic biliary atresia. Electron microscopy revealed disordered canalicular microvilli, which were often inverted (ie, projected into the cytoplasm, rather than the canalicular lumen).</p><p>Absence of villin gene expression is thought to be the mechanism causing this disorder. Villin is a protein involved in binding actin and arranging actin fibers in bundles, which are necessary for generating and maintaining anatomically normal microvilli. The human villin gene has been mapped to chromosome 2q35-36 [<a href="#rid131">131</a>]. The protein is expressed in the microvilli of brush-border surfaces in the gastrointestinal tract and kidney [<a href="#rid132">132</a>]. Interestingly, patients with abnormal villin gene expression do not exhibit clinical features of malabsorption, pancreatic abnormality, or renal disease.</p><p>Villin gene knockout mice show an abnormal response to intracellular calcium and develop colonic ulcers when fed with dextran sulfate [<a href="#rid133">133</a>]. However, in contrast to the human cases, no obvious liver phenotype was found. The mechanistic basis of these discrepancies is unknown.</p><p class="headingAnchor" id="H315610526"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116713.html" rel="external">"Society guideline links: Inherited liver disease"</a>.) </p><p class="headingAnchor" id="H91191006"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Elimination of conjugated bilirubin in bile is affected in several inherited disorders that work through different mechanisms. In all these situations, the abnormality of biliary excretion of bilirubin is shared with excretory defect of all or some other organic anions, bile salts, or phospholipids. (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dubin-Johnson syndrome is characterized clinically by mild icterus and is caused by defective canalicular excretion of conjugated bilirubin and many other organic anions. The liver is black. Otherwise, patients are asymptomatic, although mild constitutional complaints such as vague abdominal pains and weakness can occur. (See <a class="local">'Dubin-Johnson syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rotor syndrome is a rare disorder characterized by chronic conjugated and unconjugated hyperbilirubinemia without evidence of hemolysis. The defect is in the reuptake of the fraction of conjugated bilirubin, which is secreted into the sinusoidal blood by hepatocytes. (See <a class="local">'Rotor syndrome'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial hepatocellular cholestasis includes several inherited disorders including progressive familial intrahepatic cholestasis (subclassified into three types) and benign recurrent intrahepatic cholestasis. (See <a class="local">'Familial hepatocellular cholestasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two genetic disorders characterized by bile canalicular and structural anomalies have been well-described: Alagille syndrome and abnormal villin expression. (See <a class="local">'Bile canalicular and structural anomalies of known genetic basis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Liu C, Aronow BJ, Jegga AG, et al. Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis. Gastroenterology 2007; 132:119.</a></li><li><a class="nounderline abstract_t">Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339:1217.</a></li><li><a class="nounderline abstract_t">DUBIN IN, JOHNSON FB. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore) 1954; 33:155.</a></li><li><a class="nounderline abstract_t">SPRINZ H, NELSON RS. Persistent non-hemolytic hyperbilirubinemia associated with lipochrome-like pigment in liver cells: report of four cases. Ann Intern Med 1954; 41:952.</a></li><li><a class="nounderline abstract_t">DUBIN IN. Chronic idiopathic jaundice; a review of fifty cases. Am J Med 1958; 24:268.</a></li><li><a class="nounderline abstract_t">Cohen L, Lewis C, Arias IM. Pregnancy, oral contraceptives, and chronic familial jaundice with predominantly conjugated hyperbilirubinemia (Dubin-Johnson syndrome). Gastroenterology 1972; 62:1182.</a></li><li><a class="nounderline abstract_t">Shani M, Seligsohn U, Gilon E, et al. Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med 1970; 39:549.</a></li><li><a class="nounderline abstract_t">DITTRICH H, SEIFERT E. [On the behavior of pigment and biligraffin excretion in a patient with Dubin-Johnson syndrome]. Acta Hepatosplenol 1962; 9:45.</a></li><li><a class="nounderline abstract_t">Morita M, Kihara T. Intravenous cholecystography and metabolism of meglumine iodipamide (Biligrafin) in Dubin-Johnson syndrome. Radiology 1971; 99:57.</a></li><li><a class="nounderline abstract_t">ESSNER E, NOVIKOFF AB. Human hepatocellular pigments and lysosomes. J Ultrastruct Res 1960; 3:374.</a></li><li><a class="nounderline abstract_t">Swartz HM, Sarna T, Varma RR. On the natural and excretion of the hepatic pigment in the Dubin-Johnson syndrome. Gastroenterology 1979; 76:958.</a></li><li><a class="nounderline abstract_t">Rubinstein ZJ, Seligsohn U, Modan M, Shani M. Hepatic computerized tomography in the Dubin-Johnson syndrome: increased liver density as a diagnostic aid. Comput Radiol 1985; 9:315.</a></li><li><a class="nounderline abstract_t">BILLING BH, WILLIAMS R, RICHARDS TG. DEFECTS IN HEPATIC TRANSPORT OF BILIRUBIN IN CONGENITAL HYPERBILIRUBINAEMIA: AN ANALYSIS OF PLASMA BILIRUBIN DISAPPEARANCE CURVES. Clin Sci 1964; 27:245.</a></li><li><a class="nounderline abstract_t">SCHOENFIELD LJ, McGILL DB, HUNTON DB, et al. Studies of chronic idiopathic jaundice (Dubin-Johnson syndrome). I. Demonstration of hepatic excretory defect. Gastroenterology 1963; 44:101.</a></li><li><a class="nounderline abstract_t">Erlinger S, Dhumeaux D, Desjeux JF, Benhamou JP. Hepatic handling of unconjugated dyes in the Dubin-Johnson syndrome. Gastroenterology 1973; 64:106.</a></li><li><a class="nounderline abstract_t">Nakata F, Oyanagi K, Fujiwara M, et al. Dubin-Johnson syndrome in a neonate. Eur J Pediatr 1979; 132:299.</a></li><li><a class="nounderline abstract_t">Koskelo P, Toivonen I, Adlercreutz H. Urinary coproporphyrin isomer distribution in the Dubin-Johnson syndrome. Clin Chem 1967; 13:1006.</a></li><li><a class="nounderline abstract_t">Kondo T, Kuchiba K, Shimizu Y. Coproporphyrin isomers in Dubin-Johnson syndrome. Gastroenterology 1976; 70:1117.</a></li><li><a class="nounderline abstract_t">Seligsohn U, Shani M, Ramot B, et al. Hereditary deficiency of blood clotting factor VII and Dubin-Johnson syndrome in an Israeli family. Isr J Med Sci 1969; 5:1060.</a></li><li><a class="nounderline abstract_t">Seligsohn U, Shani M, Ramot B, et al. Dubin-Johnson syndrome in Israel. II. Association with factor-VII deficiency. Q J Med 1970; 39:569.</a></li><li><a class="nounderline abstract_t">Levanon M, Rimon S, Shani M, et al. Active and inactive factor VII in Dubin-Johnson syndrome with factor-VII deficiency, hereditary factor-VII deficiency and on coumadin administration. Br J Haematol 1972; 23:669.</a></li><li><a class="nounderline abstract_t">Cornelius CE. Organic anion transport in mutant sheep with congenital hyperbilirubinemia. Arch Environ Health 1969; 19:852.</a></li><li><a class="nounderline abstract_t">Alpert S, Mosher M, Shanske A, Arias IM. Multiplicity of hepatic excretory mechanisms for organic anions. J Gen Physiol 1969; 53:238.</a></li><li><a class="nounderline abstract_t">Arias IM, Bernstein L, Roffler R, et al. Black liver diseases in Corriedale sheep: Metabolism of tritiated epinephrine and incorporation of isotope into the hepatic pigment in vivo. J Clin Invest 1965; 44:1026.</a></li><li><a class="nounderline abstract_t">Kitamura T, Alroy J, Gatmaitan Z, et al. Defective biliary excretion of epinephrine metabolites in mutant (TR-) rats: relation to the pathogenesis of black liver in the Dubin-Johnson syndrome and Corriedale sheep with an analogous excretory defect. Hepatology 1992; 15:1154.</a></li><li><a class="nounderline abstract_t">Jansen PL, van Klinken JW, van Gelder M, et al. Preserved organic anion transport in mutant TR- rats with a hepatobiliary secretion defect. Am J Physiol 1993; 265:G445.</a></li><li><a class="nounderline abstract_t">Kitamura T, Jansen P, Hardenbrook C, et al. Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia. Proc Natl Acad Sci U S A 1990; 87:3557.</a></li><li><a class="nounderline abstract_t">Jansen PL, Peters WH, Lamers WH. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 1985; 5:573.</a></li><li><a class="nounderline abstract_t">Oude Elferink RP, Meijer DK, Kuipers F, et al. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim Biophys Acta 1995; 1241:215.</a></li><li><a class="nounderline abstract_t">Schulman FY, Montali RJ, Bush M, et al. Dubin-Johnson-like syndrome in golden lion tamarins (Leontopithecus rosalia rosalia). Vet Pathol 1993; 30:491.</a></li><li><a class="nounderline abstract_t">Nishida T, Hardenbrook C, Gatmaitan Z, Arias IM. ATP-dependent organic anion transport system in normal and TR- rat liver canalicular membranes. Am J Physiol 1992; 262:G629.</a></li><li><a class="nounderline abstract_t">Ishikawa T, Müller M, Klünemann C, et al. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem 1990; 265:19279.</a></li><li><a class="nounderline abstract_t">Kobayashi K, Sogame Y, Hara H, Hayashi K. Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. J Biol Chem 1990; 265:7737.</a></li><li><a class="nounderline abstract_t">Jedlitschky G, Leier I, Buchholz U, et al. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 1994; 54:4833.</a></li><li><a class="nounderline abstract_t">Nishida T, Gatmaitan Z, Roy-Chowdhry J, Arias IM. Two distinct mechanisms for bilirubin glucuronide transport by rat bile canalicular membrane vesicles. Demonstration of defective ATP-dependent transport in rats (TR-) with inherited conjugated hyperbilirubinemia. J Clin Invest 1992; 90:2130.</a></li><li><a class="nounderline abstract_t">Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8:67.</a></li><li><a class="nounderline abstract_t">Paulusma CC, Bosma PJ, Zaman GJ, et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996; 271:1126.</a></li><li><a class="nounderline abstract_t">Allikmets R, Gerrard B, Hutchinson A, Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet 1996; 5:1649.</a></li><li><a class="nounderline abstract_t">Tsujii H, König J, Rost D, et al. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 1999; 117:653.</a></li><li><a class="nounderline abstract_t">Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999; 64:739.</a></li><li><a class="nounderline abstract_t">Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997; 25:1539.</a></li><li><a class="nounderline abstract_t">Wada M, Toh S, Taniguchi K, et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998; 7:203.</a></li><li><a class="nounderline abstract_t">Kajihara S, Hisatomi A, Mizuta T, et al. A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome. Biochem Biophys Res Commun 1998; 253:454.</a></li><li><a class="nounderline abstract_t">Mor-Cohen R, Zivelin A, Rosenberg N, et al. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001; 276:36923.</a></li><li><a class="nounderline abstract_t">Keitel V, Kartenbeck J, Nies AT, et al. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 2000; 32:1317.</a></li><li><a class="nounderline abstract_t">Kaplowitz N, Javitt N, Kappas A. Coproporphyrin I and 3 excretion in bile and urine. J Clin Invest 1972; 51:2895.</a></li><li><a class="nounderline abstract_t">Wolkoff AW, Cohen LE, Arias IM. Inheritance of the Dubin-Johnson syndrome. N Engl J Med 1973; 288:113.</a></li><li><a class="nounderline abstract_t">Rotor AB, Manahan L, Florentin A. Familial nonhemolytic jaundice with direct van den Bergh reaction. Acta Med Phil 1948; 5:37.</a></li><li><a class="nounderline abstract_t">Pereira-Lima JE, Utz E, Rosenberg I. Hereditary nonhemolytic conjugated hyperbilirubinemia without abnormal liver cell pigmentation: A family study. Am J Med 1966; 40:628.</a></li><li><a class="nounderline abstract_t">Wolkoff AW, Wolpert E, Pascasio FN, Arias IM. Rotor's syndrome. A distinct inheritable pathophysiologic entity. Am J Med 1976; 60:173.</a></li><li><a class="nounderline abstract_t">Wolpert E, Pascasio FM, Wolkoff AW, Arias IM. Abnormal sulfobromophthalein metabolism in Rotor's syndrome and obligate heterozygotes. N Engl J Med 1977; 296:1099.</a></li><li><a class="nounderline abstract_t">Kawasaki H, Kimura N, Irisa T, Hirayama C. Dye clearance studies in Rotor's syndrome. Am J Gastroenterol 1979; 71:380.</a></li><li><a class="nounderline abstract_t">Shimizu Y, Naruto H, Ida S, Kohakura M. Urinary coproporphyrin isomers in Rotor's syndrome: a study in eight families. Hepatology 1981; 1:173.</a></li><li><a class="nounderline abstract_t">Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology 2014; 146:1625.</a></li><li><a class="nounderline abstract_t">van de Steeg E, Stránecký V, Hartmannová H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012; 122:519.</a></li><li><a class="nounderline abstract_t">SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008; 359:789.</a></li><li><a class="nounderline abstract_t">Kenyon AP, Girling JC. Liver disease in pregnancy. Women's Health Medicine 2005; 2:26.</a></li><li><a class="nounderline abstract_t">Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child 1969; 117:112.</a></li><li><a class="nounderline abstract_t">Klomp LW, Bull LN, Knisely AS, et al. A missense mutation in FIC1 is associated with greenland familial cholestasis. Hepatology 2000; 32:1337.</a></li><li><a class="nounderline abstract_t">Bull LN, van Eijk MJ, Pawlikowska L, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998; 18:219.</a></li><li><a class="nounderline abstract_t">Eppens EF, van Mil SW, de Vree JM, et al. FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. J Hepatol 2001; 35:436.</a></li><li><a class="nounderline abstract_t">Strautnieks SS, Kagalwalla AF, Tanner MS, et al. Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. Am J Hum Genet 1997; 61:630.</a></li><li><a class="nounderline abstract_t">Strautnieks SS, Byrne JA, Pawlikowska L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 2008; 134:1203.</a></li><li><a class="nounderline abstract_t">Wang L, Soroka CJ, Boyer JL. The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. J Clin Invest 2002; 110:965.</a></li><li><a class="nounderline abstract_t">Jansen PL, Müller MM. Progressive familial intrahepatic cholestasis types 1, 2, and 3. Gut 1998; 42:766.</a></li><li><a class="nounderline abstract_t">Knisely AS, Strautnieks SS, Meier Y, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006; 44:478.</a></li><li><a class="nounderline abstract_t">Jara P, Hierro L, Martínez-Fernández P, et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med 2009; 361:1359.</a></li><li><a class="nounderline abstract_t">Keitel V, Burdelski M, Vojnisek Z, et al. De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis. Hepatology 2009; 50:510.</a></li><li><a class="nounderline abstract_t">Siebold L, Dick AA, Thompson R, et al. Recurrent low gamma-glutamyl transpeptidase cholestasis following liver transplantation for bile salt export pump (BSEP) disease (posttransplant recurrent BSEP disease). Liver Transpl 2010; 16:856.</a></li><li><a class="nounderline abstract_t">Patel KR, Harpavat S, Finegold M, et al. Post-transplant Recurrent Bile Salt Export Pump Disease: A Form of Antibody-mediated Graft Dysfunction and Utilization of C4d. J Pediatr Gastroenterol Nutr 2017; 65:364.</a></li><li><a class="nounderline abstract_t">Lam P, Pearson CL, Soroka CJ, et al. Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases. Am J Physiol Cell Physiol 2007; 293:C1709.</a></li><li><a class="nounderline abstract_t">Hayashi H, Sugiyama Y. 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology 2007; 45:1506.</a></li><li><a class="nounderline abstract_t">Gonzales E, Grosse B, Schuller B, et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology 2015; 62:558.</a></li><li><a class="nounderline abstract_t">Jacquemin E, De Vree JM, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120:1448.</a></li><li><a class="nounderline abstract_t">Nies AT, Gatmaitan Z, Arias IM. ATP-dependent phosphatidylcholine translocation in rat liver canalicular plasma membrane vesicles. J Lipid Res 1996; 37:1125.</a></li><li><a class="nounderline abstract_t">de Vree JM, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998; 95:282.</a></li><li><a class="nounderline abstract_t">Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001; 120:1459.</a></li><li><a class="nounderline abstract_t">Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis 2007; 2:29.</a></li><li><a class="nounderline abstract_t">Ziol M, Barbu V, Rosmorduc O, et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008; 135:131.</a></li><li><a class="nounderline abstract_t">Fein F, Hermelin B, Becker MC, et al. Acute recurrent biliary pancreatitis associated with the ABCB4 gene mutation. Gastroenterol Clin Biol 2007; 31:106.</a></li><li><a class="nounderline abstract_t">Sambrotta M, Strautnieks S, Papouli E, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet 2014; 46:326.</a></li><li><a class="nounderline abstract_t">Zhou S, Hertel PM, Finegold MJ, et al. Hepatocellular carcinoma associated with tight-junction protein 2 deficiency. Hepatology 2015; 62:1914.</a></li><li><a class="nounderline abstract_t">Jacquemin E, Hermans D, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25:519.</a></li><li><a class="nounderline abstract_t">Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 2009; 4:1.</a></li><li><a class="nounderline abstract_t">Squires RH, Ng V, Romero R, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Hepatology 2014; 60:362.</a></li><li><a class="nounderline abstract_t">De Vloo C, Nevens F. Cholestatic pruritus : an update. Acta Gastroenterol Belg 2019; 82:75.</a></li><li><a class="nounderline abstract_t">Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012; 56:1391.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51:237.</a></li><li><a class="nounderline abstract_t">Kremer AE, Bolier R, van Dijk R, et al. Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis 2014; 32:637.</a></li><li><a class="nounderline abstract_t">Webb GJ, Rahman SR, Levy C, Hirschfield GM. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther 2018; 47:1213.</a></li><li><a class="nounderline abstract_t">Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102:1528.</a></li><li><a class="nounderline abstract_t">Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002; 95:547.</a></li><li><a class="nounderline abstract_t">Thébaut A, Habes D, Gottrand F, et al. Sertraline as an Additional Treatment for Cholestatic Pruritus in Children. J Pediatr Gastroenterol Nutr 2017; 64:431.</a></li><li><a class="nounderline abstract_t">Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988; 95:130.</a></li><li><a class="nounderline abstract_t">Arnell H, Bergdahl S, Papadogiannakis N, et al. Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis. J Pediatr Surg 2008; 43:1312.</a></li><li><a class="nounderline abstract_t">van der Woerd WL, Kokke FT, van der Zee DC, Houwen RH. Total biliary diversion as a treatment option for patients with progressive familial intrahepatic cholestasis and Alagille syndrome. J Pediatr Surg 2015; 50:1846.</a></li><li><a class="nounderline abstract_t">Kurbegov AC, Setchell KD, Haas JE, et al. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 2003; 125:1227.</a></li><li><a class="nounderline abstract_t">Schukfeh N, Metzelder ML, Petersen C, et al. Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. J Pediatr Surg 2012; 47:501.</a></li><li><a class="nounderline abstract_t">Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, et al. Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998; 33:220.</a></li><li><a class="nounderline abstract_t">Kaliciński PJ, Ismail H, Jankowska I, et al. Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass. Eur J Pediatr Surg 2003; 13:307.</a></li><li><a class="nounderline abstract_t">Englert C, Grabhorn E, Richter A, et al. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation 2007; 84:1361.</a></li><li><a class="nounderline abstract_t">Lykavieris P, van Mil S, Cresteil D, et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol 2003; 39:447.</a></li><li><a class="nounderline abstract_t">de Vree JM, Ottenhoff R, Smith AJ, et al. Long term effects of hepatocyte transplantation in an animal model of progressive familial intrahepatic cholestasis (abstract). Hepatology 1999; 30(4 pt.2):409A.</a></li><li><a class="nounderline abstract_t">De Vree JM, Ottenhoff R, Bosma PJ, et al. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000; 119:1720.</a></li><li><a class="nounderline abstract_t">SUMMERSKILL WH, WALSHE JM. Benign recurrent intrahepatic "obstructive" jaundice. Lancet 1959; 2:686.</a></li><li><a class="nounderline abstract_t">de Pagter AG, van Berge Henegouwen GP, ten Bokkel Huinink JA, Brandt KH. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives? Gastroenterology 1976; 71:202.</a></li><li><a class="nounderline abstract_t">Tygstrup N, Jensen B. Intermittent intrahepatic cholestasis of unknown etiology in five young males from the Faroe Islands. Acta Med Scand 1969; 185:523.</a></li><li><a class="nounderline abstract_t">Tygstrup N, Steig BA, Juijn JA, et al. Recurrent familial intrahepatic cholestasis in the Faeroe Islands. Phenotypic heterogeneity but genetic homogeneity. Hepatology 1999; 29:506.</a></li><li><a class="nounderline abstract_t">Klomp LW, Vargas JC, van Mil SW, et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 2004; 40:27.</a></li><li><a class="nounderline abstract_t">SUMMERSKILL WH. THE SYNDROME OF BENIGN RECURRENT CHOLESTASIS. Am J Med 1965; 38:298.</a></li><li><a class="nounderline abstract_t">Summerfield JA, Scott J, Berman M, et al. Benign recurrent intrahepatic cholestasis: studies of bilirubin kinetics, bile acids, and cholangiography. Gut 1980; 21:154.</a></li><li><a class="nounderline abstract_t">Biempica L, Gutstein S, Arias IM. Morphological and biochemical studies of benign recurrent cholestasis. Gastroenterology 1967; 52:521.</a></li><li><a class="nounderline abstract_t">van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004; 127:379.</a></li><li><a class="nounderline abstract_t">Kubitz R, Keitel V, Scheuring S, et al. Benign recurrent intrahepatic cholestasis associated with mutations of the bile salt export pump. J Clin Gastroenterol 2006; 40:171.</a></li><li><a class="nounderline abstract_t">van der Woerd WL, van Mil SW, Stapelbroek JM, et al. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract Res Clin Gastroenterol 2010; 24:541.</a></li><li><a class="nounderline abstract_t">Stapelbroek JM, van Erpecum KJ, Klomp LW, et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006; 43:51.</a></li><li><a class="nounderline abstract_t">Saich R, Collins P, Ala A, et al. Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur J Gastroenterol Hepatol 2005; 17:585.</a></li><li><a class="nounderline abstract_t">Uegaki S, Tanaka A, Mori Y, et al. Successful treatment with colestimide for a bout of cholestasis in a Japanese patient with benign recurrent intrahepatic cholestasis caused by ATP8B1 mutation. Intern Med 2008; 47:599.</a></li><li><a class="nounderline abstract_t">Alagille D, Estrada A, Hadchouel M, et al. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 1987; 110:195.</a></li><li><a class="nounderline abstract_t">Alagille D. Alagille syndrome today. Clin Invest Med 1996; 19:325.</a></li><li><a class="nounderline abstract_t">Emerick KM, Rand EB, Goldmuntz E, et al. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999; 29:822.</a></li><li><a class="nounderline abstract_t">Subramaniam P, Knisely A, Portmann B, et al. Diagnosis of Alagille syndrome-25 years of experience at King's College Hospital. J Pediatr Gastroenterol Nutr 2011; 52:84.</a></li><li><a class="nounderline abstract_t">Oda T, Elkahloun AG, Meltzer PS, Chandrasekharappa SC. Identification and cloning of the human homolog (JAG1) of the rat Jagged1 gene from the Alagille syndrome critical region at 20p12. Genomics 1997; 43:376.</a></li><li><a class="nounderline abstract_t">Gottrand F, Clavey V, Fruchart JC, Farriaux JP. Lipoprotein pattern and plasma lecithin cholesterol acyl transferase activity in children with Alagille syndrome. Atherosclerosis 1995; 115:233.</a></li><li><a class="nounderline abstract_t">Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 2001; 49:431.</a></li><li class="breakAll">Maralixibat chloride solution. US Food and Drug Administration (FDA) approved product information. Revised April 5, 2022. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64000394-1ef6-4e76-8ba8-11f25ba1b167.</li><li><a class="nounderline abstract_t">Hoffenberg EJ, Narkewicz MR, Sondheimer JM, et al. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr 1995; 127:220.</a></li><li><a class="nounderline abstract_t">Clerici C, Gentili G, Dozzini G, et al. [Chronic therapy with ursodeoxycholic acid in a child with Alagille syndrome]. Pediatr Med Chir 1993; 15:521.</a></li><li><a class="nounderline abstract_t">Hofbauer LC, Mrozek-Lasota A, Jelinek T, et al. [Endocrinologic and metabolic complications of Alagille syndrome]. Med Klin (Munich) 1997; 92:528.</a></li><li><a class="nounderline abstract_t">Phillips MJ, Azuma T, Meredith SL, et al. Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood. Lancet 2003; 362:1112.</a></li><li><a class="nounderline abstract_t">Pringault E, Robine S, Louvard D. Structure of the human villin gene. Proc Natl Acad Sci U S A 1991; 88:10811.</a></li><li><a class="nounderline abstract_t">Bretscher A, Weber K. Villin is a major protein of the microvillus cytoskeleton which binds both G and F actin in a calcium-dependent manner. Cell 1980; 20:839.</a></li><li><a class="nounderline abstract_t">Ferrary E, Cohen-Tannoudji M, Pehau-Arnaudet G, et al. In vivo, villin is required for Ca(2+)-dependent F-actin disruption in intestinal brush borders. J Cell Biol 1999; 146:819.</a></li></ol></div><div id="topicVersionRevision">Topic 3584 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241866" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9780343" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular pathogenesis of cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13193360" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13208040" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Persistent non-hemolytic hyperbilirubinemia associated with lipochrome-like pigment in liver cells: report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13508683" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic idiopathic jaundice; a review of fifty cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5050316" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pregnancy, oral contraceptives, and chronic familial jaundice with predominantly conjugated hyperbilirubinemia (Dubin-Johnson syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5532959" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13886601" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [On the behavior of pigment and biligraffin excretion in a patient with Dubin-Johnson syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5548689" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intravenous cholecystography and metabolism of meglumine iodipamide (Biligrafin) in Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13820842" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Human hepatocellular pigments and lysosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/220131" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : On the natural and excretion of the hepatic pigment in the Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4064636" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hepatic computerized tomography in the Dubin-Johnson syndrome: increased liver density as a diagnostic aid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14220904" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : DEFECTS IN HEPATIC TRANSPORT OF BILIRUBIN IN CONGENITAL HYPERBILIRUBINAEMIA: AN ANALYSIS OF PLASMA BILIRUBIN DISAPPEARANCE CURVES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13992285" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Studies of chronic idiopathic jaundice (Dubin-Johnson syndrome). I. Demonstration of hepatic excretory defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4683844" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hepatic handling of unconjugated dyes in the Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/520367" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dubin-Johnson syndrome in a neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6054688" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Urinary coproporphyrin isomer distribution in the Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1269872" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Coproporphyrin isomers in Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5369704" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hereditary deficiency of blood clotting factor VII and Dubin-Johnson syndrome in an Israeli family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5499883" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dubin-Johnson syndrome in Israel. II. Association with factor-VII deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4675008" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Active and inactive factor VII in Dubin-Johnson syndrome with factor-VII deficiency, hereditary factor-VII deficiency and on coumadin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5389192" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Organic anion transport in mutant sheep with congenital hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5764745" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Multiplicity of hepatic excretory mechanisms for organic anions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Black liver diseases in Corriedale sheep: Metabolism of tritiated epinephrine and incorporation of isotope into the hepatic pigment in vivo</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1592353" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Defective biliary excretion of epinephrine metabolites in mutant (TR-) rats: relation to the pathogenesis of black liver in the Dubin-Johnson syndrome and Corriedale sheep with an analogous excretory defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214066" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Preserved organic anion transport in mutant TR- rats with a hepatobiliary secretion defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2333302" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4018730" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7640297" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8116141" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dubin-Johnson-like syndrome in golden lion tamarins (Leontopithecus rosalia rosalia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1566846" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : ATP-dependent organic anion transport system in normal and TR- rat liver canalicular membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2172249" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2335503" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7915193" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430236" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Two distinct mechanisms for bilirubin glucuronide transport by rat bile canalicular membrane vesicles. Demonstration of defective ATP-dependent transport in rats (TR-) with inherited conjugated hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1282354" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : ABC transporters: from microorganisms to man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8599091" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8894702" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10464142" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10053008" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185779" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9425227" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9878557" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477083" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11093739" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5080415" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Coproporphyrin I and 3 excretion in bile and urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4682034" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inheritance of the Dubin-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Familial nonhemolytic jaundice with direct van den Bergh reaction</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hereditary nonhemolytic conjugated hyperbilirubinemia without abnormal liver cell pigmentation: A family study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/766621" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Rotor's syndrome. A distinct inheritable pathophysiologic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/850521" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Abnormal sulfobromophthalein metabolism in Rotor's syndrome and obligate heterozygotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/453129" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dye clearance studies in Rotor's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7286897" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Urinary coproporphyrin isomers in Rotor's syndrome: a study in eight families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24704527" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22232210" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650507" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : SLCO1B1 variants and statin-induced myopathy--a genomewide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Liver disease in pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5762004" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11093741" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A missense mutation in FIC1 is associated with greenland familial cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500542" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11682026" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326328" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18395098" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370274" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9691911" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Progressive familial intrahepatic cholestasis types 1, 2, and 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871584" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797282" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Recurrence of bile salt export pump deficiency after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19642168" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20583290" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Recurrent low gamma-glutamyl transpeptidase cholestasis following liver transplantation for bile salt export pump (BSEP) disease (posttransplant recurrent BSEP disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945205" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Post-transplant Recurrent Bile Salt Export Pump Disease: A Form of Antibody-mediated Graft Dysfunction and Utilization of C4d.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855769" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538928" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25716872" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11313315" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8725163" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : ATP-dependent phosphatidylcholine translocation in rat liver canalicular plasma membrane vesicles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9419367" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11313316" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562004" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18482588" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17273143" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Acute recurrent biliary pancreatitis associated with the ABCB4 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24614073" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mutations in TJP2 cause progressive cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25921221" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hepatocellular carcinoma associated with tight-junction protein 2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9049190" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19133130" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Progressive familial intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24782219" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30888758" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cholestatic pruritus : an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473838" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501929" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : EASL Clinical Practice Guidelines: management of cholestatic liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25034299" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Advances in pathogenesis and management of pruritus in cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29468705" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403073" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145394" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27557426" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Sertraline as an Additional Treatment for Cholestatic Pruritus in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3371608" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18639688" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26319776" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Total biliary diversion as a treatment option for patients with progressive familial intrahepatic cholestasis and Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14517804" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424345" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498390" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14618520" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18049123" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Liver transplantation in children with progressive familial intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12927934" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Long term effects of hepatocyte transplantation in an animal model of progressive familial intrahepatic cholestasis (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113093" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13835689" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Benign recurrent intrahepatic "obstructive" jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/939378" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5807632" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Intermittent intrahepatic cholestasis of unknown etiology in five young males from the Faroe Islands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9918928" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Recurrent familial intrahepatic cholestasis in the Faeroe Islands. Phenotypic heterogeneity but genetic homogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15239083" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Characterization of mutations in ATP8B1 associated with hereditary cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14256726" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : THE SYNDROME OF BENIGN RECURRENT CHOLESTASIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7380339" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Benign recurrent intrahepatic cholestasis: studies of bilirubin kinetics, bile acids, and cholangiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6019971" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Morphological and biochemical studies of benign recurrent cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15300568" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394881" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Benign recurrent intrahepatic cholestasis associated with mutations of the bile salt export pump.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955958" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374853" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827452" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18379143" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Successful treatment with colestimide for a bout of cholestasis in a Japanese patient with benign recurrent intrahepatic cholestasis caused by ATP8B1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3806290" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8889270" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Alagille syndrome today.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051485" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Features of Alagille syndrome in 92 patients: frequency and relation to prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21119543" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Diagnosis of Alagille syndrome-25 years of experience at King's College Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9268641" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Identification and cloning of the human homolog (JAG1) of the rat Jagged1 gene from the Alagille syndrome critical region at 20p12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7661882" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Lipoprotein pattern and plasma lecithin cholesterol acyl transferase activity in children with Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511567" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Outcome of liver disease in children with Alagille syndrome: a study of 163 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511567" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Outcome of liver disease in children with Alagille syndrome: a study of 163 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7636645" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8159589" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : [Chronic therapy with ursodeoxycholic acid in a child with Alagille syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9411201" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : [Endocrinologic and metabolic complications of Alagille syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14550699" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1961750" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Structure of the human villin gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6893424" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Villin is a major protein of the microvillus cytoskeleton which binds both G and F actin in a calcium-dependent manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459016" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : In vivo, villin is required for Ca(2+)-dependent F-actin disruption in intestinal brush borders.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
